Study #2019-0513
Phase II study of Dose-Reduced Consolidation Radiation Therapy in Patients with Diffuse Large B-cell Lymphoma
MD Anderson Study Status
Not Accepting
Treatment Agent
Description
This phase II study will evaluate whether a reduction in radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity . Hypothesis: The radiation dose and treatment volume can be safely reduced from 30 Gy to 20 Gy while maintaining high rates of local control in patients who had a negative PET-CT scan following rituximab - containing chemotherapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Diffuse Large B Cell Lymphoma
Study phase:
Not applicable
Physician name:
Chelsea Pinnix
Department:
Radiation Oncology
For general questions about clinical trials:
1-844-335-2276
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.